Visualize: ASCO 2018's winners and losers
Oncology’s biggest yearly event wrapped up in Chicago earlier this week, where our editor-in-chief John Carroll brought you coverage on the biggest boons and blunders for ASCO presenters.
There was the widely-covered Nektar implosion, in which the company fumbled the presentation of data on NKTR-214 — spooking investors and tanking the company’s stock as low as 42% in the days after. Then Roche dumped its PhIII PI3K effort on taselisib, and its Tecentriq/chemo combo came up short in comparison to rivals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.